AN2 Therapeutics Rises on Positive Chagas Disease Trial Data, ADC Therapeutics Falls

AN2 Therapeutics saw its stock rise following positive early-stage trial data for its Chagas disease therapy, while ADC Therapeutics experienced a decline after confirmatory trial data for its lymphoma treatment.